What follows is a look at stocks in the S&P 500 displaying unusual volume in today's trading session.
Fears of global economic contagion sent the markets falling for the second day in a row, pushing the Dow below 10,000. But Bill Smead, CEO and CIO of Smead Capital Management and Craig Hodges, co-portfolio manager at The Hodges Fund said they still remain bullish on the markets.
The euro fell broadly on Monday, after the Spanish central bank's takeover of a savings bank added to jitters about debt problems in some of the weak euro zone countries. Where should investors be putting their money? Jason Trennert, chief investment strategist and managing partner at Strategas Research Partners, shared his views and investment strategies.
As the Amgen Tour of California—the largest cycling event in the U.S.—was hitting its stride, the Wall Street Journal broke the story that former Tour de France champion Floyd Landis admitted to doping. He also implicated others, including some riding in this week's Tour, like Lance Armstrong. Armstrong again denies the allegations.
Drug developer Celgene is expected to release data on from two studies in coming weeks, and the bulls are looking for a rally.
The Dow clawed back in late trading Wednesday. Technology and industrials gained while health-care and telecom shares continued to drag.
Amgen says better sales of its anti-infection drugs helped lift first-quarter profit 15 percent, but cautions that health care reform measures will tamp down full-year results.
What follows is a roundup of corporate earnings reports for Wednesday, April 21.
Stocks wobbled in mid-afternoon trading Wednesday. Technology and industrials gained while health-care and telecom stocks continued to drag.
Stocks pushed higher Wednesday, led by techs and banks as optimism about the economic recovery gained strength and worries about the Goldman Sach charges subsided.
The bond markets have been garnering a lot of attention in recent months. How should investors get involved and what should they watch for? Marilyn Cohen, president of Envision Capital, shared her insights.
U.S. stock index futures struggled to find direction ahead of the open Wednesday as investors braced for the next batch of corporate earnings.
On the eve of the 10-year anniversary of the dot-com bubble bursting the stock stat mavens here at CNBC sliced and diced all sorts of data on share price performance since March 10, 2000.
They looked like hot stocks. So how are the traders playing Qualcomm, Amgen and more now that they’ve been burned?
Markets barely edged upward on Monday as Europe debt worries continue. Where are the best places to put your money now? Greg Merlino, president and founder of Ameriway Financial Services, and Ethan Anderson, portfolio manager at Rehmann Financial, shared their market strategies.
So far this year, the performance of the biotechnology index has been strong. So is there room for more growth in the sector? Mark Schoenebaum, managing director and senior research analyst at Deutsche Bank Securities shared his stock picks.
Nearly every city and state wants biopharma. They fiercely compete for the relatively clean industry and the well-paid, highly educated jobs it brings.
Pfizer, the world's largest drugmaker, is scheduled to report fourth-quarter results before the opening bell on Wednesday, February 3. Here is a look at how Pfizer shares traded during the most recent earnings reports.
Considering Pfizer, Sanofi and Glaxo are among the many Pharma names reporting this week, how should you game the space?
Markets opened mixed on Thursday. What should investors expect from stocks going forward? Ray Harrison, founder of Harrison Financial Group, and Bill Smead, CEO and CIO of Smead Capital Management, shared their investment plays.